伴随诊断联合研究和许可协议（2010-2024）

Companion Diagnostic Collaboration and Licensing Deals 2010-2024

出版日期: 2024年11月01日 | 出版商:

Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告审查了伴随诊断合作和许可协议，详细瞭解和分析了公司如何以及为何进行伴随诊断合作。

介绍
过去几年的伴随诊断合约
最活跃的伴随诊断承包商
伴随诊断合约：依合约类型
伴随诊断合约：按治疗领域
伴随诊断合约：按行业部门
伴随诊断合约条款与条件
- 伴随诊断合约标题金额
- 伴随诊断合约预付款
- 伴随诊断合约的里程碑付款
- 伴随诊断版税率

第3章主要伴随诊断合约

介绍
按价值排名最高的伴随诊断合同

第 4 章：最活跃的同侪诊断合约公司

介绍
最活跃的同侪诊断承包商
最活跃的伴随诊断承包商简介

第5章陪诊合约名录

介绍
配套诊断合约目录

第 6 章伴随诊断合约：依技术类型

合约目录
合约目录 - 伴随诊断合约：按公司 (AZ)
合约目录 - 伴随诊断合约：依合约类型
合约目录 - 伴随诊断合约：按治疗领域
定义合约类型
关于Biopharma Research Ltd
目前的合作伙伴
目前协议
目前合作伙伴最近报告的标题

简介目录

Product Code: CP2106

Companion Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of companion diagnostic deals from 2010 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 530 companion diagnostic deals announced since 2010 including financial terms where available including links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of companion diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2010.

Chapter 3 provides an overview of the leading companion diagnostic deals since 2010. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostic dealmaking with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of companion diagnostic deals signed and announced since Jan 2010, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since Jan 2010. The chapter is organized by specific companion diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in companion diagnostic deal making since 2010.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2010
Browse companion diagnostic collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Companion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Companion Diagnostic Collaboration and Licensing Deals includes:

Trends in companion diagnostic dealmaking in the biopharma industry
Directory of companion diagnostic deal records covering pharmaceutical and biotechnology
The leading companion diagnostic deals by value
Most active companion diagnostic licensing dealmakers
Companion Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in companion diagnostic dealmaking

2.1. Introduction
2.2. Companion diagnostic deals over the years
2.3. Most active companion diagnostic dealmakers
2.4. Companion diagnostic deals by deal type
2.5. Companion diagnostic deals by therapy area
2.6. Companion diagnostic deals by industry sector
2.7. Deal terms for companion diagnostic deals
- 2.7.1 Companion diagnostic deals headline values
- 2.7.2 Companion diagnostic deal upfront payments
- 2.7.3 Companion diagnostic deal milestone payments
- 2.7.4 Companion diagnostic royalty rates